探讨盐酸氨溴索联合头孢克肟治疗小儿喘息性支气管炎的临床效果

Exploring the Clinical Effect of Ambroxol Hydrochloride Combined with Cefixime in the Treatment of Children with Asthmatic Bronchitis

目的 探讨对喘息性支气管炎患儿采用盐酸氨溴索+头孢克肟完成治疗后获得临床效果。方法 方便选取2018年1月—2020年12月收治的68例喘息性支气管炎患儿进行治疗研究;随机分为常规组(选择头孢克肟药物完成治疗)和研究组(选择盐酸氨溴索+头孢克肟药物完成治疗),各34例;比较两组患儿治疗总有效率、炎性因子水平[血清白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]、临床症状改善时间(喘息消失时间、退热时间、哮鸣音消失时间、咳嗽消失时间、住院时间)、不良反应(呕吐、腹泻、发热)总发生率。结果 同常规组治疗总有效率(76.47%)比较,研究组(97.06%)更高,差异有统计学意义(χ^(2)=4.610,P<0.05);治疗前,研究组IL-8、TNF-α、CRP水平同常规组比较,差异无统计学意义(P>0.05);治疗后,研究组IL-8、TNF-α、CRP水平均低于常规组,差异有统计学意义(P<0.05);研究组各临床症状改善时间均短于常规组,差异有统计学意义(P<0.05);研究组不良反应(呕吐、腹泻、发热)总发生率(8.82%)低于常规组(41.18%),差异有统计学意义(χ^(2)=9.490,P<0.05)。结论 盐酸氨溴索+头孢克肟药物有效应用,可显著提升患儿治疗效果,有效降低IL-8、TNF-α、CRP水平,显著缩短喘息消失时间、退热时间、哮鸣音消失时间、咳嗽消失时间、住院时间,显著减少呕吐、腹泻、发热等不良反应,可促进喘息性支气管炎患儿总体治疗水平、预后水平显著提升。

Objective To explore the clinical effect of ambroxol hydrochloride+cefixime in children with asthmatic bronchitis.Methods A total of 68 children with asthmatic bronchitis who were admitted from January 2018 to December 2020 were conveniently selected for treatment research.Randomly divided into routine group(choose cefixime drug to complete treatment)and study group(choose ambroxol hydrochloride+cefixime drug to complete treatment),34 cases in each.The total effective rate,inflammatory factor levels[serum interleukin-8(IL-8),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP)],clinical symptom improvement time(time to disappearance of wheezing,time to fever reduction,time to disappearance of wheeze,time to disappearance of cough,time to hospitalization)and the total incidence of adverse reactions(vomiting,diarrhea,fever)were compared between the two groups.Results Compared with the routine group(76.47%),the study group(97.06%)was higher,the difference was statistically significant(χ^(2)=4.610,P<0.05).Before treatment,the levels of IL-8,TNF-αand CRP in the study group were not statistically significant difference from those in the routine group(P>0.05).After treatment,the levels of IL-8,TNF-αand CRP in the study group were lower than those in the routine group,the difference was statistically significant(P<0.05).The improvement time of each clinical symptom in the study group was shorter than that in the routine group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions (vomiting, diarrhea, fever) in the study group (8.82%) was lower than that in the routine group (41.18%), and the difference was statistically significant (χ^(2)=9.490,P<0.05). Conclusion The effective application of ambroxol hydrochloride + cefixime can significantly improve the therapeutic effect of children, and effectively reduce the levels of IL-8, TNF-α and CRP. The disappearance time of wheezing, antipyretic time, wheezing sound disappearance time, cough disappearance time and hospitalization time were shortened significantly. It can significantly reduce the adverse reactions such as vomiting, diarrhea, and fever, and can significantly improve the overall treatment level and prognosis of children with asthmatic bronchitis.